CN Patent

CN108778260A — 选择白血病对象的治疗方案的分析和方法

Assigned to Oregon Health and Science University · Expires 2018-11-09 · 8y expired

What this patent protects

用于鉴定适合用CPX‑351治疗的患有癌症的对象的诊断方法包括对来自候选对象的细胞进行遗传和离体测试。CPX‑351和FLT‑3抑制剂联合治疗可改善CPX‑351摄取和毒性。

USPTO Abstract

用于鉴定适合用CPX‑351治疗的患有癌症的对象的诊断方法包括对来自候选对象的细胞进行遗传和离体测试。CPX‑351和FLT‑3抑制剂联合治疗可改善CPX‑351摄取和毒性。

Drugs covered by this patent

Patent Metadata

Patent number
CN108778260A
Jurisdiction
CN
Classification
—
Expires
2018-11-09
Drug substance claim
No
Drug product claim
No
Assignee
Oregon Health and Science University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.